PE Tech Report


Like this article?

Sign up to our free newsletter

Milestone Pharmaceuticals closes USD17m Series B Financing

Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company in Phase 2, has closed a USD17 million Series B financing. 

The round was led by Domain Associates and included participation from all of Milestone's existing investors including Fonds de solidarité FTQ (FSTQ), Pappas Ventures, BDC Capital, GO Capital, and iNovia Capital. The funding will be used to complete Phase 2 clinical development of MSP-2017. In connection with this financing, Domain's Debra Liebert will join Milestone's board of directors.

"We are excited to have a premier life sciences investor such as Domain join Milestone," says Philippe Douville, Chief Executive Officer of Milestone. "We've made great progress since our Series A financing with advances on nasal formulations resulting in novel IP, completion of preclinical work, positive Phase 1 results, and filing of an IND. I look forward to working with Debra on the board as we continue development of MSP-2017 in Phase 2."

Like this article? Sign up to our free newsletter